Every 10-Q that Catheter Precision, Inc. (VTAK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VTAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTAK filings page.
Catheter Precision, Inc. (VTAK) reported sharply higher revenue but remains loss-making and under a going concern warning. For the six months ended June 30, 2026, total revenues rose to $1.5 million from $0.4 million a year earlier, driven by $0.9 million of new private aviation service revenue from the FLYTE acquisition and growth in cardiac products, including VIVO and LockeT.
Despite this, the company recorded a net loss of $5.0 million and used $5.7 million in operating cash. As of June 30, 2026, cash and cash equivalents were $0.6 million, with a working capital deficit of $10.9 million and an accumulated deficit of $314.5 million. Management states there is substantial doubt about the ability to continue as a going concern and plans to rely on additional equity and debt financings, including a multi-tranche Series C and Series D preferred stock program and related warrant exercises.
Total assets increased to $36.9 million from $15.9 million at year-end 2025, reflecting $13.0 million of goodwill and higher intangible assets from acquiring 100% of private aviation operator FLYTE and its subsidiaries. The business is now managed in two segments: cardiac electrophysiology and private aviation.
Catheter Precision, Inc. reported Q1 2026 results showing a larger business but continued heavy losses and tight liquidity. Revenue rose to $432,000 from $143,000, driven by growth in VIVO and LockeT product sales and the addition of private aviation services.
The company posted a net loss of $1.7 million, improved from a $4.0 million loss a year earlier, as operating loss narrowed and fair value gains on deferred consideration offset other charges. Total assets increased to $35.1 million, including $22.3 million of intangibles and $9.7 million of goodwill, largely from acquiring 100% of private aviation platform FLYTE and its subsidiary Ponderosa.
Cash and cash equivalents were only $0.4 million at March 31, 2026, with a working capital deficit of $18.5 million. Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern and plans to rely on additional equity and debt financings, including recent and potential issuances of Series C and Series D preferred stock and warrant exercises, to fund operations while it builds out both the cardiac electrophysiology and private aviation segments.
Catheter Precision, Inc. reported Q3 2025 results showing small but growing sales and ongoing losses, alongside a going concern warning. Revenue was $226,000 for the quarter (vs. $96,000 a year ago) and $581,000 for the nine months (vs. $271,000). Net loss attributable to the company was $2.251 million in Q3 and $11.405 million year to date.
Cash and cash equivalents were $1.075 million as of September 30, 2025, with a working capital deficit of $2.9 million and accumulated deficit of $303.8 million. Total liabilities were $19.0 million, including royalties payable due to related parties of $10.743 million. Management states there is substantial doubt about the ability to continue as a going concern.
To fund operations, the company completed a private placement on May 12, 2025 collecting $1.5 million in cash plus QHSLab notes, and sold 868,582 shares under an ATM launched May 19, 2025 for gross proceeds of $4.0 million. A 1‑for‑19 reverse stock split became effective on August 15, 2025. Shares outstanding were 1,668,375 as of November 7, 2025.
Catheter Precision, Inc. (VTAK) reported accelerating product sales and continued investment in new technologies while also recording material operating losses and liquidity strain. Product revenue totaled $355 thousand for the six months ended June 30, 2025, up from $175 thousand a year earlier, with U.S. sales of $308 thousand in the period. The company incurred a six-month net loss of $9.5 million and used $4.6 million of cash in operating activities.
Balance sheet items highlight short-term pressure: cash and cash equivalents were $0.8 million, working capital showed a $2.6 million deficit, and accumulated deficit reached $301.5 million. Material financing and corporate actions in 2025 included a May PIPE that generated $1.5 million in cash (and two convertible notes received as consideration), an ATM program that produced $1.7 million gross through June 30, 2025, formation of subsidiaries Cardionomix and KardioNav, acquisition of CPNS System assets, and an April 2025 U.S. patent for LockeT. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.